•
1 2

International Myeloma Foundation

IMF Publication - Understanding Tecvayli™

IMF Publication - Understanding Tecvayli™

$0.00 USD
$0.00 USD
Sale Sold out
Shipping calculated at checkout.
Tecvayli™ (teclistmab-cqyv) is the first in a drug class of bispecific antibodies approved by the FDA to treat myeloma. Tecvayli is indicated for patients with relapsed or refractory myeloma who have received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Tecvayli is an immunotherapy, a treatment that enhances the patient’s own immune system to attack their myeloma cells.

Materials

Shipping & Returns

Dimensions

Care Instructions

View full details

Image with text

Pair text with an image to focus on your chosen product, collection, or blog post. Add details on availability, style, or even provide a review.

  • Free Shipping

    Pair text with an image to focus on your chosen product, collection, or blog post. Add details on availability, style, or even provide a review.

  • Hassle-Free Exchanges

    Pair text with an image to focus on your chosen product, collection, or blog post. Add details on availability, style, or even provide a review.